Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

   Completed · Phase 2 · Respiratory Syncytial Virus

   NCT06143046 · ModernaTX, Inc. · 17 U.S. investigators

   $1.2Mresearch payments

2. Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

   Active, not recruiting · Phase 1, Phase 2 · Parkinson Disease

   NCT04127578 · Eli Lilly and Company · 6 U.S. investigators

   $1.2Mresearch payments

3. A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

   Recruiting · Phase 3 · Diffuse Large B-cell Lymphoma (DLBCL)

   NCT06091865 · Regeneron Pharmaceuticals, Inc. · 18 U.S. investigators

   $1.2Mresearch payments

4. Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

   Active, not recruiting · Phase 3 · Women at Risk for Pregnancy

   NCT03633799 · Sebela Women's Health Inc. · 38 U.S. investigators

   $1.2Mresearch payments

5. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

   Recruiting · Phase 3 · Amyloidosis

   NCT06563895 · Eidos Therapeutics, Inc. · 36 U.S. investigators

   $1.1Mresearch payments

6. A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

   Completed · Phase 1 · Healthy Volunteers

   NCT06433505 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $1.1Mresearch payments

7. A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

   Recruiting · Phase 3 · Hypogammaglobulinemia

   NCT05645107 · Grifols Therapeutics LLC · 5 U.S. investigators

   $1.1Mresearch payments

8. Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

   Completed · Phase 1, Phase 2 · Respiratory Syncytial Virus Immunization

   NCT05639894 · Sanofi Pasteur Inc. · 22 U.S. investigators

   $1.1Mresearch payments

9. A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

   Completed · Phase 4 · Upper Limb Spasticity

   NCT04936542 · Ipsen Pharma Sas · 49 U.S. investigators

   $1.1Mresearch payments

10. Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

    Completed · Phase 1 · Healthy Participants

    NCT07158398 · Deciphera Pharmaceuticals Inc. · 1 U.S. investigator

    $1.1Mresearch payments

11. Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

    Active, not recruiting · Phase 3 · Endometriosis

    NCT04333576 · AbbVie Inc. · 81 U.S. investigators

    $1.1Mresearch payments

12. A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

    Completed · Phase 3 · Type 2 Diabetes

    NCT05971940 · Eli Lilly and Company · 48 U.S. investigators

    $1.1Mresearch payments

13. A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

    Active, not recruiting · Phase 1 · Breast Cancer

    NCT05307705 · Eli Lilly and Company · 17 U.S. investigators

    $1.1Mresearch payments

14. Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

    Completed · Phase 3 · Atopic Dermatitis

    NCT04392154 · Eli Lilly and Company · 83 U.S. investigators

    $1.1Mresearch payments

15. Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Active, not recruiting · Phase 2 · Extensive-stage Small-cell Lung Cancer

    NCT05280470 · Daiichi Sankyo Inc. · 18 U.S. investigators

    $1.1Mresearch payments

16. A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

    Active, not recruiting · Phase 2 · Moderate to Severe Atopic Dermatitis

    NCT06136741 · E.r. Squibb & Sons, L.l.c. · 28 U.S. investigators

    $1.1Mresearch payments

17. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Recruiting · Phase 3 · Obesity

    NCT06672939 · Eli Lilly and Company · 13 U.S. investigators

    $1.1Mresearch payments

18. A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    Completed · Phase 2 · Overweight

    NCT05536804 · Eli Lilly and Company · 11 U.S. investigators

    $1.1Mresearch payments

19. Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

    Recruiting · Phase 2, Phase 3 · Neoplasms

    NCT03435796 · Celgene Corporation · 67 U.S. investigators

    $1.1Mresearch payments

20. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT05461300 · Galderma Laboratories, L.P. · 16 U.S. investigators

    $1.1Mresearch payments

21. Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

    Active, not recruiting · Phase 1 · Recurrent B-Cell Non-Hodgkin Lymphoma

    NCT05627245 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $1.1Mresearch payments

22. Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

    Active, not recruiting · Phase 1, Phase 2 · Clinical Stage IV Cutaneous Melanoma AJCC v8

    NCT04557956 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $1.1Mresearch payments

23. A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

    Active, not recruiting · Phase 3 · Crohn's Disease

    NCT04232553 · Eli Lilly and Company · 51 U.S. investigators

    $1.1Mresearch payments

24. A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

    Terminated · Phase 1 · Solid Tumor, Adult

    NCT05381909 · Beone Medicines Ltd. · 15 U.S. investigators

    $1.1Mresearch payments

25. Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

    Completed · Phase 3 · Generalized Myasthenia Gravis

    NCT04225871 · UCB SA · 28 U.S. investigators

    $1.1Mresearch payments

26. A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

    Terminated · Phase 2 · Hidradenitis Suppurativa

    NCT06028230 · Sanofi US Services Inc. · 18 U.S. investigators

    $1.1Mresearch payments

27. Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

    Active, not recruiting · Phase 2 · B-Cell Non-Hodgkin Lymphoma

    NCT06242834 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $1.1Mresearch payments

28. A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

    Active, not recruiting · Phase 1 · Renal Cell Carcinoma

    NCT04707248 · Daiichi Sankyo Inc. · 32 U.S. investigators

    $1.1Mresearch payments

29. Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

    Active, not recruiting · Phase 1 · Extensive Stage Lung Small Cell Carcinoma

    NCT05353439 · Ipsen Biopharmaceuticals, Inc · 2 U.S. investigators

    $1.0Mresearch payments

30. DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

    Active, not recruiting · Phase 3 · Low-grade Glioma

    NCT05566795 · Day One Biopharmaceuticals · 28 U.S. investigators

    $1.0Mresearch payments

31. A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

    Completed · Phase 3 · Allergic Conjunctivitis

    NCT06602739 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $1.0Mresearch payments

32. Fabry Disease Registry & Pregnancy Sub-registry

    Recruiting · Fabry Disease

    NCT00196742 · Sanofi US Services Inc. · 63 U.S. investigators

    $1.0Mresearch payments

33. Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

    Active, not recruiting · Phase 2 · High Grade Ovarian Cancer

    NCT05456685 · AbbVie Inc. · 25 U.S. investigators

    $1.0Mresearch payments

34. A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT05254743 · Eli Lilly and Company · 19 U.S. investigators

    $1.0Mresearch payments

35. Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

    Completed · Phase 2 · Osteoarthritis

    NCT04627038 · Eli Lilly and Company · 38 U.S. investigators

    $1.0Mresearch payments

36. A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

    Completed · Phase 2 · Chronic Rhinosinusitis With Nasal Polyps

    NCT06454240 · Sanofi US Services Inc. · 15 U.S. investigators

    $1.0Mresearch payments

37. A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

    Active, not recruiting · Phase 2 · Atopic Dermatitis

    NCT06718101 · AbbVie Inc. · 18 U.S. investigators

    $1.0Mresearch payments

38. An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

    Recruiting · Phase 1, Phase 2 · Vanishing White Matter Disease

    NCT05757141 · AbbVie Inc. · 3 U.S. investigators

    $1.0Mresearch payments

39. A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

    Terminated · Phase 2, Phase 3 · Leiomyosarcoma

    NCT05269355 · Ptc Therapeutics, Inc. · 15 U.S. investigators

    $1.0Mresearch payments

40. Performance Evaluation of the VIDAS TB-IGRA Assay.

    Completed · Active Tuberculosis

    NCT04048018 · Biomerieux Inc · 6 U.S. investigators

    $1.0Mresearch payments

41. A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

    Active, not recruiting · Phase 2 · Waldenstrom Macroglobulinemia

    NCT05952037 · Beigene, Ltd. · 16 U.S. investigators

    $1.0Mresearch payments

42. Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

    Active, not recruiting · Phase 3 · Cutaneous Squamous Cell Carcinoma

    NCT03969004 · Regeneron Pharmaceuticals, Inc. · 18 U.S. investigators

    $1.0Mresearch payments

43. A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

    Enrolling by invitation · Phase 3 · Stereotypical Prolonged Seizures

    NCT05076617 · UCB SA · 49 U.S. investigators

    $1.0Mresearch payments

44. PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

    Active, not recruiting · Phase 2 · Prolymphocytic Leukemia

    NCT01589302 · AbbVie Inc. · 1 U.S. investigator

    $1.0Mresearch payments

45. An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

    Completed · Phase 2 · Rheumatoid Arthritis

    NCT05848258 · Eli Lilly and Company · 14 U.S. investigators

    $1.0Mresearch payments

46. A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

    Terminated · Phase 2 · Alopecia Areata

    NCT06444451 · Sanofi US Services Inc. · 18 U.S. investigators

    $999,763research payments

47. Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

    Completed · Phase 1, Phase 2 · Meningococcal Immunisation

    NCT06128733 · Sanofi Pasteur Inc. · 32 U.S. investigators

    $997,833research payments

48. A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

    Recruiting · Phase 1 · Epithelial Ovarian Cancer

    NCT06469281 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

    $996,275research payments

49. Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

    Active, not recruiting · Phase 2 · Advanced NSCLC

    NCT05609578 · Mirati Therapeutics, Inc. · 20 U.S. investigators

    $991,218research payments

50. ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

    Completed · Paroxysmal Atrial Fibrillation

    NCT06526546 · Boston Scientific Corporation · 25 U.S. investigators

    $990,823research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.